Cambrex

Cambrex Expands Peptide Manufacturing Capabilities in US

CDMO Cambrex announced that Snapdragon Chemistry, a Cambrex company, has expanded its active pharmaceutical ingredient (API) facility in Waltham, Massachusetts

Cambrex Opens New Stability Storage Facility

Today, Cambrex announced its stability storage business, Q1 Scientific, and opened a new cGMP facility in Durham, North Carolina, expanding its capacity for environmentally controlled stability storage services to North America's pharmaceutical, medical device, and life sciences industries.

Cambrex Announces New Peptide Synthesis Manufacturing Technology

Cambrex announced that Snapdragon Chemistry, a Cambrex company, has developed a new liquid-phase peptide synthesis (LPPS) technology utilizing active pharmaceutical ingredient (API) batch reactors and continuous flow.

Expert Statement: Frank Ferrante, Cambrex

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.

The Evolution of the CDMO Industry

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine. CHEManager asked executives and industry experts from a broad range of CDMOs to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.

Noramco Acquires Drug Product Business Unit from Cambrex

Noramco, a US producer of active pharmaceutical ingredients (APIs), has completed the acquisition of the Cambrex drug product business unit previously known as Halo Pharmaceuticals. Financial details were not disclosed.

Cambrex Takes Snapdragon Chemistry

US CDMO Cambrex has agreed to buy Snapdragon Chemistry, a compatriot company specializing in developing continuous flow and batch processes for APIs. Snapdragon is based in Waltham, Massachusetts, where it employs 74 people.

Cambrex Invests in US R&D Facility

Cambrex is investing in a new R&D facility in Minneapolis, Minnesota, USA, expanding its capacity for small molecule development and manufacturing.

Cambrex Upgrades Estonia Facility

US CDMO Cambrex has upgraded its facility in Tallin, Estonia. The installation of a new 160-liter reactor train at the kilogram-scale laboratory has expanded Cambrex’s capabilities to manufacture material for clinical trials and allow early-phase projects to be developed further prior to technical transfer and scale-up.

Facing Strong Headwinds

So far, the pharmaceutical industry — including CMOs/CDMOs — has responded well to the outbreak of the Covid-19 pandemic.

Cambrex Expands Swedish Drugs Facility

Cambrex is spending $3.6 million to expand flexible drug substance manufacturing at its site in Karlskoga, Sweden. Engineering has already begun, and work is expected to be completed by November 2020.

Flow Chemistry - A Mature Technology still on the Rise

The change in many chemical companies’ product portfolio away from commodities to customer-specific specialties is one of the current challenges facing the process industry.

Flow Chemistry: A Mature Technology still on the Rise

The change in many chemical companies’ product portfolio away from commodities to customer-specific specialties is one of the current challenges facing the process industry.

Experts Statements: Matthew Moorcroft, Cambrex

The Pharma CDMO Challenge

Permira to Acquire Cambrex for $60 per Share

Cambrex to Buy Avista Pharma Solutions

Cambrex to Upgrade Generic API Manufacturing Facilities at Milan Site

M&A in Pharma and CRO/CMO Industry

A Wide Spectrum of Contract Services

Cambrex to Acquire Halo Pharma

Both Positive and Negative Effects

M&A in Pharma and CRO/CMO Industry

Cambrex Expands Charles City API Plant

Cambrex Invests in Swedish cGMP Facility

Cambrex Hikes High Point Capacity

Tom Vadaketh Appointed as CFO of Cambrex

Experts Statements: Ingrid Hegbom Ekman, Cambrex

Experts Statements: Kurt J. Kiewel, Cambrex

The Winning Formula

Cambrex Validates Milan API Pilot Plant

Cambrex Expands API Services With PharmaCore

Cambrex Announces Investment & Expansion

Opportunities in Drug Development and Manufacturing

Growth in the global oncology drug market is an important measure of opportunities in drug development and manufacturing, including for contract manufacturers of active pharmaceutical ingredients (APIs) and finished drug products.

The Winning Formula